Literature DB >> 10812195

Mechanisms of action of valproate: a commentatory.

C U Johannessen1.   

Abstract

Valproate, one of the major antiepileptic drugs used today, has besides its wide use in both generalized and partial epilepsies, several new approved indications including the treatment of bipolar disorders, neuropathic pain, and as a migraine prophylaxis. This wide spectrum of activities is reflected by several different mechanisms of action, which are discussed in this review. With regard to the antiepileptic effect of VPA, a special emphasis is put on the effect on the GABAergic system and the effect on enzymes like succinate semialdehyde dehydrogenase (SSA-DH), GABA transaminase (GABA-T), and alpha-ketoglutarate dehydrogenase, related to the tricarboxylic acid (TCA) cycle and thereby cerebral metabolism. In vitro studies have shown that VPA is a potent inhibitor of SSA-DH. In brain homogenates, GABA-T is inhibited at high concentrations only. Besides affecting the GABA-shunt, VPA might also inhibit the TCA cycle at the alpha-ketoglutarate dehydrogenase step. The effect of VPA on excitatory neurotransmission and on excitatory membranes are mechanisms likely to be responsible for the 'mood-stabilizing' effect as well as in the treatment of migraine. GABA-mediated responses may be involved in neuropathic pain. But still there are many aspects of the mechanisms of action of VPA that remain unknown.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10812195     DOI: 10.1016/s0197-0186(00)00013-9

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  93 in total

Review 1.  Developmental neuropathology of environmental agents.

Authors:  Lucio G Costa; Michael Aschner; Annabella Vitalone; Tore Syversen; Offie Porat Soldin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

Review 2.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Anti-Epileptic Drug Targets Ewing Sarcoma.

Authors:  Shubhalaxmi Kayarthodi; Yasuo Fujimura; Jinbo Fang; Sharif Morsalin; Veena N Rao; E Shyam P Reddy
Journal:  J Pharm Sci Pharmacol       Date:  2014-06-01

4.  Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour.

Authors:  J P Webster; P H L Lamberton; C A Donnelly; E F Torrey
Journal:  Proc Biol Sci       Date:  2006-04-22       Impact factor: 5.349

5.  The neuroprotective effect of curcumin and Nigella sativa oil against oxidative stress in the pilocarpine model of epilepsy: a comparison with valproate.

Authors:  Heba S Aboul Ezz; Yasser A Khadrawy; Neveen A Noor
Journal:  Neurochem Res       Date:  2011-07-13       Impact factor: 3.996

6.  Ca2+/calmodulin-dependent protein kinase II--a target for sodium valproate?

Authors:  T A Savina; O A Balashova; T G Shchipakina
Journal:  Neurosci Behav Physiol       Date:  2008-01

7.  Case files of the Children's Hospital of Michigan Regional Poison Control Center: the use of carnitine for the management of acute valproic acid toxicity.

Authors:  Abhishek Katiyar; Cynthia Aaron
Journal:  J Med Toxicol       Date:  2007-09

Review 8.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

9.  Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder.

Authors:  Richard P Bazinet; Margaret T Weis; Stanley I Rapoport; Thad A Rosenberger
Journal:  Psychopharmacology (Berl)       Date:  2005-12-13       Impact factor: 4.530

10.  Lamotrigine and valproic acid have different effects on motorcortical neuronal excitability.

Authors:  Xingbao Li; Raffaella Ricci; Charles H Large; Berry Anderson; Ziad Nahas; Mark S George
Journal:  J Neural Transm (Vienna)       Date:  2009-02-24       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.